blood test for SARS-COV2 serology
Diagnostic Testeach person who will accept to participate will have a bood test for a SARS-COV2 serology
NCT Number: NCT04470648
Study of COVID-19 seroprevalence in precarious population living in shelters of Samusocial de Paris and in staff working in these centers during COVID-19 epidemic.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Haltes pour femmes, Paris, France
After emergence of a new coronavirus (Severe Acute Respiratory Syndrome Coronavirus 2, SARS-CoV2) responsible for a cluster of respiratory infection at Wuhan, China, on January, 7th 2020, first cases were diagnosed in France in January 24th 2020.
Health care components of Samusocial de Paris (Lits Haltes Soins Santé (LHSS)) were created in 2006. They provide medical care for homeless people and people in social distress not needing an hospitalization. Sometimes there are 3 persons in a bedroom.
In december 2018, a special shelter for isolated women or women in precarious situations opened.
Because of the living conditions in these centers and the difficulty for these populations to respect social distancing and hygiene recommendations.
A first case of COVID-19 was identified on March 8th 2020 in one of these healthcare centers. Other cases were detected in the same center, then in another center on March 16th, then in the dormitory of the women shelter on March 30th.
A recent study showed an important prevalence of SARS-COV2 in residents of a homeless shelter in Boston (36%), most of them were asymptomatic.
Seroprevalence studies are done in general population or in health care workers, but don't include vulnerable people.
It seemed important to us to describe the epidemic in these centers and to study COVID-19 seroprevalence in these particular populations.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
each person who will accept to participate will have a bood test for a SARS-COV2 serology
Time frame: 6 months
Primary objective is to evaluate SARS-COV2 seroprevalence in people hosted and health care workers of 3 centers of Samusocial de Paris where COVID19 epidemics occured
Time frame: 6 months
Measure of morbidity in the participating population in the 3 centers
Time frame: 6 months
Number of deaths related to Covid-19 during the epidemic in the 3 centers
Time frame: 6 months
Time frame: 6 months
Time frame: 10 months
2 blood tests 4 and 8 months afetr the first one
Institut National de la Santé Et de la Recherche Médicale, France
Other Gov
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05125887
COVID-19, Coronaviridae Infections
Limoges, France
View Trial DetailsNCT04590222
COVID-19, Coronaviridae Infections
Le Kremlin-Bicêtre, France
View Trial DetailsNCT06181292
COVID-19, Coronaviridae Infections
Badalona, Barcelona, Spain
View Trial DetailsNCT05172024
COVID-19, Coronaviridae Infections
Birmingham, Alabama, United States
View Trial Details